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Abstract
The Centers for Disease Control and Prevention (CDC) had an annual budget of approximately $327 million to fund health
departments and community-based organizations for core HIV testing and prevention programs domestically between
2001 and 2006. Annual HIV incidence has been relatively stable since the year 2000 [1] and was estimated at 48,600 cases in
2006 and 48,100 in 2009 [2]. Using estimates on HIV incidence, prevalence, prevention program costs and benefits, and
current spending, we created an HIV resource allocation model that can generate a mathematically optimal allocation of the
Division of HIV/AIDS Prevention’s extramural budget for HIV testing, and counseling and education programs. The model’s
data inputs and methods were reviewed by subject matter experts internal and external to the CDC via an extensive
validation process. The model projects the HIV epidemic for the United States under different allocation strategies under a
fixed budget. Our objective is to support national HIV prevention planning efforts and inform the decision-making process
for HIV resource allocation. Model results can be summarized into three main recommendations. First, more funds should be
allocated to testing and these should further target men who have sex with men and injecting drug users. Second,
counseling and education interventions ought to provide a greater focus on HIV positive persons who are aware of their
status. And lastly, interventions should target those at high risk for transmitting or acquiring HIV, rather than lower-risk
members of the general population. The main conclusions of the HIV resource allocation model have played a role in the
introduction of new programs and provide valuable guidance to target resources and improve the impact of HIV prevention
efforts in the United States.
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Introduction
At the end of 2006, HIV prevalence among the adult and
adolescent population in the United States was estimated at 1.1
million, with 21% unaware of their seropositivity [3]. A 2008
survey of 21 cities indicated that 19% of men who have sex with
men (MSM) were HIV infected and 44% of those were unaware of
their infection [4]. Annual HIV incidence has been relatively
stable since the year 2000 [1] and was estimated at 48,600 cases in
2006 and 48,100 in 2009 [2]. More than half (56%) of these cases
occurred among MSM, while injection drug use and heterosexual
contact accounted for 11% and 29% of incident cases, respectively
in 2006 [2]. Black and Hispanic populations in the US are
disproportionately affected by HIV. In 2006, 44% and 18% of
new HIV infections were among black individuals and Hispanics,
respectively, while these populations represent 13% and 15% of
the general US adult population, respectively [2].
Approximately 84% of all federal funding for domestic HIV
prevention is channeled through the Division of HIV/AIDS
Prevention (DHAP) at the Centers for Disease Control and
Prevention (CDC) [5]. In 2006, DHAP had an extramural budget
of approximately $650 million; of that, approximately $327 million
was used to fund health departments and community-based
organizations for core HIV testing and prevention programs
domestically.
Using the best and most current available estimates on HIV
incidence, prevalence, prevention program costs and benefits, and
current spending, we created an HIV resource allocation model
that can generate the mathematically optimal allocation of
DHAP’s budget. We explore the allocation of DHAP’s budget
and therefore focus specifically on the main prevention programs
currently funded by DHAP, HIV testing, and counseling and
education programs. Evidence supporting biomedical measures
such as circumcision, pre-exposure prophylaxis (PrEP) and
antiretroviral therapy (ART) for HIV prevention has recently
been released [6,7,8]. However, medical services and funding for
treatment are not allowable expenses for CDC’s HIV prevention
funds, and HIV care and treatment is administered by other
federal agencies. The model projects the HIV epidemic for the
United States under different allocation strategies of a fixed
budget. It selects the allocation scenario that minimizes incidence
over a five-year time horizon. Our objective was to support
DHAP’s planning efforts and inform the decision-making process
for HIV resource allocation.
Methods
The HIV resource allocation model is comprised of two
components that interact: an epidemic model that projects HIV
infections over time given a specific funding allocation scenario,
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scenarios to the epidemic model, stopping with the allocation that
yields the fewest new infections.
The Epidemic Model
The epidemic model is a dynamic compartmental model
defined by a set of difference equations. Details of the model’s
structure and methods are provided elsewhere [9]. The population
considered was first structured by HIV transmission risk group and
gender: male high risk heterosexuals (HRH), female HRH, men
who have sex with men (MSM), male injection drug users (IDUs)
and female IDUs. These five subgroups were then further stratified
by three race/ethnicities defined as black, Hispanic and all others;
where all others are primarily (97%) whites but also included
Asians, Pacific Islanders, Alaska natives and American Indians.
Studies have demonstrated that those aware of their HIV infection
tend to engage in safer sexual behavior with uninfected partners
[10,11,12], and that transmission rates among those HIV infected
and unaware are on average 3.5 times that of those who are
infected and aware of their infection [13]. Therefore, each of the
15 population subgroups was divided into three compartments:
those susceptible to HIV infection, those who are HIV-positive but
undiagnosed, and those diagnosed with HIV.
New infections occur as a result of effective contacts between
those who are susceptible and both diagnosed and undiagnosed
HIV positive populations. To identify the effective contact rates,
first, we use the method suggested by Marks (2006) to estimate the
percentage of HIV transmissions from the HIV-positive diagnosed
for each of the 15 subgroups [13]. Then, using these data and
assumptions about racial and sexual mixing between population
subgroups, we establish two 15 by 15 matrices: one for the number
of new infections in the susceptible population subgroups that
result from contact with the undiagnosed subgroups and one for
the number of new infections in the susceptible population
subgroups that result from contact with the diagnosed subgroups.
Knowing the size of each subgroup compartment, we identify the
effective contact rates by solving for them in the incidence
equation of a Susceptible-Infected model [14]. This process is
detailed elsewhere [9].
The effect of antiretroviral therapy on transmissions is implicit
in our model. First, deriving contact rates from incidence and
prevalence avoids the need to parse the effects of each factor that
contributes to HIV transmission because the number of incident
HIV cases is indicative of the effects of all these factors such as
number of partners, number of unsafe acts, transmission
probabilities, viral load and stage of disease. Also, the percentage
of HIV transmissions from the HIV-positive diagnosed assumes
that a proportion of those HIV-positive diagnosed have an
undetectable viral load and cannot transmit the virus [13].
Input Data for the Epidemic Model
The estimated size of the HIV-infected population in the US,
aged 13–64, for each high-risk population subgroup was based on
DHAP’s surveillance data, with three adjustments [15]. First, we
adjusted these data for completeness of reporting, which represents
cases that have been diagnosed but will never be reported [16].
Second, for the year 2006, HIV estimates are only available for 33
states. Therefore, we extrapolated these HIV estimates to the 50
states and the District of Columbia using the ratio of estimated
AIDS prevalence in those 33 states to the AIDS prevalence in the
50 states and the District of Columbia. Third, we adjusted for
undiagnosed cases using the proportion of HIV-infected persons
who are aware of their infection by race/ethnicity, gender and
transmission category [3].
The model also requires estimates of the sizes of the high-risk
population subgroups. Our primary source of data for HRH and
MSM was cycle 6 (2002) of the National Survey of Family Growth
(NSFG) [17]. The size of the HRH population was based on the
number of respondents who self-reported any of the following risk
behaviors in the past year: STD treatment; HIV positive, IDU or
five or more opposite sex partners; sex in exchange for money or
drugs; crack cocaine use; and for females, MSM sex partner. Our
definition of HRH excludes all MSM and IDUs. The size of the
MSM population was based on the estimated number of male
respondents who self-reported sex with another male but not illicit
drug injection in the past year. Due to underreporting of MSM
behavior, we used the upper end of the confidence interval in our
estimation. The latest national estimate for the total number of
IDUs is 1,543,746 for the year 2002 [18]. We used estimates of
injection drug use among black and white residents of US
metropolitan areas to break down the national estimate by race/
ethnicity [19] and used CDC’s HIV Counseling and Testing
System (CTS) to break down the estimates by gender [20].
We analyzed DHAP’s programmatic budget data by line item
to estimate the current allocation to each of the 15 population
subgroups for testing, and counseling and education intervention;
the allocation totals $327 million and we refer to it as the baseline
allocation.
The current version of our inputs is based on the most recent
data available and we intend to repopulate our model with
updated inputs annually.
The Optimization Model
The optimization model chooses the amounts to allocate each
year toward interventions and population subgroups to minimize
new infections over a five-year time horizon. The model is
informed by the costs and effectiveness of the prevention
interventions under consideration. Potential funding amounts
can be limited by three factors: the maximum annual budget,
upper and lower bounds on the amounts that can be allocated to
an intervention and population subgroup, and the minimum and
maximum proportions of a population subgroup that can be
reached by an intervention. The formulation of the optimization
model is provided elsewhere [9].
HIV Prevention Interventions
We considered the two types of HIV prevention interventions
historically funded by CDC: HIV testing, and individual and
group-level counseling and education. At the narrowest level,
interventions could be targeted any of the susceptible or infected
compartments of the population subgroups and at the broadest
level interventions could be aimed at the general U.S. population.
Individuals who are susceptible to infection are not distinguishable
from those who are HIV-infected but undiagnosed and are
therefore targeted together.
Typically, intervention costs per person increase with the level
of targeting so that more narrowly targeted interventions are
costlier per person than broadly targeted ones. When testing is
aimed broadly to the general US adult population, we estimated
the per person cost of testing based on the cost of opt-out testing in
emergency department settings [21], and the cost of a CDC-led
expanded testing program. When testing is targeted to high risk
populations, we based our cost estimates of testing on the average
of several published studies reporting the cost of testing in STD
clinic settings and the cost of testing in outreach settings [21,22].
We identified studies of individual-, and group-based counseling
and education interventions with statistically significant positive
between-group outcomes and for which sufficient data were
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the participant’s estimated annual acquisition or transmission rate.
Estimates of the cost per person and effect size of counseling and
education targeted to HIV-positive, diagnosed persons were based
on five studies [23,24,25,26,27]; and these estimates for interven-
tions targeted to HIV-negative, high-risk persons were based on
four studies [28,29,30]. All costs were adjusted to 2009 US dollars
[31]. Data and sources are presented in Table 1.
In the epidemic model, testing interventions derive their
prevention effects from moving HIV-infected but undiagnosed
individuals to the HIV-infected and diagnosed compartment
where the effective contacts rates are smaller. Counseling and
education interventions derive their prevention effects from
removing a portion of those reached from their respective
compartments for the duration of effect of the intervention. After
12 months and for the remainder of the time horizon, the effect of
counseling and education interventions was assumed to wane by
90% relative to the effect size at 12 months.
Validation of Model Structure and Inputs
The HIV resource allocation model’s structure and methods
were reviewed and validated by four subject matter experts
external to the CDC.
We developed a data definition document in which the input
data were grouped into 15 categories; for each category, we report
the data values, data sources and derivation method. We
established an internal validation process where subject matter
experts, internal to DHAP, were assigned to each data group and
tasked with revising and approving the corresponding data
definition document. Once all data definition documents were
validated, an internal review panel of 25 members, including but
not limited to the assigned experts, was convened. The panel met
twice, reviewed all data definition documents and provided
revisions and final approval.
Data definition documents were then compiled into six
categories: three on the characteristics of the MSM, IDU and
HRH populations, and three on intervention program data
relating to costs, counseling and education outcomes and
maximum penetration rates. For each data category, we estab-
lished an external peer review committee comprised of two to four
consultants outside of CDC. The charge to each committee
entailed reviewing the corresponding data definition document,
providing a written assessment with references to alternate sources
of data where applicable, and participating in a conference call
with all respective committee members to finalize the data.
Using this internal and external validation process, we verified
all data inputs to the resource allocation model and, where
applicable, identified a realistic range of values for use in sensitivity
analysis.
We ran the model to optimality under the base case conditions
and examined how the recommended optimized allocation differs
from the current allocation of funds in terms of populations and
interventions.
We developed a univariate sensitivity analysis function in our
model to gauge the stability of the model results. This sensitivity
analysis function evaluates up to ten variables to be modified, in
sequence, according to five user-specified values. We selected key
model results and created upper and lower bounds based on a 10
percentage point increase or decrease in the proportion of the
budget allocated according to these key model results. For
example, if the model suggests allocating 54% of the total budget
to testing interventions then the upper and lower bounds were set
to 64% and 44%, respectively. We report the cases where one or
more of the bounds on the key model results have been violated
and provide the related details.
To understand how the model prioritized funding to interven-
tions and populations, we sequentially set the total budget from
$100 million to $500 million in increments of $100 million and set
the model to optimize for each of those allocations. This scenario
can supply valuable information for decision makers because it
illustrates how HIV prevention should be prioritized, given limited
budgets, to have the greatest impact on the epidemic.
Results
The epidemic estimates predicted by the model are presented in
Figure 1. The cumulative number of new HIV infections over five
years predicted by the model is 192,000 under an optimized
allocation of the $327 million budget, 223,000 in the baseline
scenario which assumes the current allocation of the $327 million
Table 1. Input data.
Parameter Value Source
Estimated size of the HIV- population, aged 13–64, in the US (2006) 1,100,000 [3]
Estimated size of the high-risk population, aged 13–64, in the US 21,300,000 [17,18,19,20]
Percentage of HIV positives unaware of their serostatus 21% [3]
Estimated number of new HIV infections in the US (2006) 48,600 [1,43]
Proportion of new infections that result from contact with an unaware positive 48% [13]
Cost of testing per positive in the general US adult population (US$ 2009) $82 [21]
Cost of testing per negative in the general US adult population (US$ 2009) $18 [21]
Cost of testing per positive in the high-risk populations (US$ 2009) $126 [21,22]
Cost of testing per negative in the high-risk populations (US$ 2009) $52 [21,22]
Per person cost of counseling and education interventions for positives (US$ 2009) $514 [23,24,25,26,27,31]
Per person cost of counseling and education interventions for high-risk populations (US$ 2009) $322 [28,29,30,31]
Effect size of counseling and education interventions for positives 18% [23,24,25,26,27]
Effect size of counseling and education interventions for high risk populations 8% [28,29,30]
Reduction in effect size of all counseling and education interventions after 12 months 90% Assumption
doi:10.1371/journal.pone.0037545.t001
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baseline allocation averts 13% of new infections when comparing
no allocation of funds and the optimized allocation averts 31% of
new infections when comparing no allocation of funds. The gap in
annual incidence between no allocation and the baseline allocation
steadily increased from 4% in the first year of the time horizon to
20% in the fifth and last year. In the first year, the incidence in the
optimized allocation represents a 9% reduction relative to the no
allocation; because the effects of decreased transmissions accumu-
late over time, this gap widens and the annual incidence in the fifth
year only represents a 48% reduction in the optimized allocation
relative to the no allocation. Over the five year horizon, the
breakdown of new infections by risk group is approximately 30%
HRH, 60% MSM and 10% IDU and is consistent across the
optimized, baseline and no allocation strategies.
The HIV resource allocation model results are presented in
Table 2. Key differences between the baseline and the optimized
allocation recommended by the model include: first, 29% of the
total budget of $327 million was allocated to the general US adult
population at the baseline, while the optimized scenario allocated
the entire budget to the MSM, IDU and heterosexual high risk
populations, and no funds to the general US adult population.
Second, 49% of the total budget was allocated to testing and 51%
to counseling and education at the baseline, while the optimized
scenario allocated 61% and 39% of the budget to testing and
counseling and education interventions, respectively. Also, 11% of
the counseling and education budget was targeted to counseling
and education for diagnosed positives at the baseline and that
percentage rose to 100% according to the model’s optimized
allocation. Lastly, the allocation to MSM increases from 23% to
51% of the total budget between the baseline and the optimized
scenario, and the allocation to at-risk blacks and Hispanics
increases from 49% to 65% of the total budget. In the optimized
scenario, funds for MSM are targeted to testing black and
Hispanic MSM and to counseling and education for diagnosed,
positive MSM.
Sensitivity Analyses
In order to assess the stability of the model results, we conducted
more than 100 one-way sensitivity analysis scenarios on more than
20 model variables. Below, we present only scenarios where
variations in the parameter values altered any of the key results
presented in Table 2 by more than ten percentage points.
Results appeared most sensitive to variations in the cost of
testing, the cost and outcome of counseling and education
interventions and the size of the MSM population. The model’s
optimized allocation to testing MSM increased by more than ten
percentage points when the cost of testing increases beyond $150
per negative and $225 per positive because testing MSM remains a
priority in spite of the cost increase and therefore the allocation to
testing MSM is proportionally greater.
The effects observed when either reducing the cost or increasing
the outcome of counseling and education programs are similar
because they improve the cost-effectiveness of counseling and
education. Under these circumstances, the overall allocation to
counseling and education programs increases, and therefore the
allocation to testing is reduced; also, the proportional allocation to
targeted MSM for both intervention types increases thereby
confirming them as a high priority risk group.
As the size of the MSM population in the model increases, the
proportion of the allocation to testing that is targeted to MSM
Figure 1. Annual and cumulative number of new HIV infections over 5 years.
doi:10.1371/journal.pone.0037545.g001
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sustained focus on MSM.
Incremental Budget Constraint Scenario
We evaluate five budget scenarios where the total budget is
set between $100 million and $500 million in increments of
$100 million. Figure 2 displays the allocation to testing and
counseling and education interventions for each budget scenar-
io. At $100 million, the budget is allocated to testing only but as
the budget increases, more funds are allocated to counseling
and education interventions and at a budget of $500 million
more funds are allocated to counseling and education interven-
tions than to testing. Figure 3 presents the allocation by risk
group. At $100 million, 84% of the budget is allocated to MSM
and the remainder to IDUs; as the budget increases, more funds
are allocated to all three risk groups. At a budget of $500
million the proportion of funds allocated to MSM, IDUs and
HRH is 55%, 16% and 29% respectively. Table 3 presents new
infections over the five-year horizon as the annual budget
increases. The marginal infections averted decrease from 38,506
to 5,906 and represent the reduction in HIV incidence for each
additional $100 million made available in the annual budget.
The total number of infections averted relative to no investment
is also presented in Table 3 along with the resulting cost per
infection averted, medical costs averted and an estimate of the
cost-savings incurred which are increasing from $13 billion to
$23 billion. The medical costs are based on the lifetime
treatment cost of an HIV infection estimated at $367,000 (US$
2009) [32].
Discussion
Our model estimates reductions in new HIV infections
associated with current and optimized HIV prevention expendi-
tures and results in three main recommendations. First, the
allocation to testing interventions should increase and further
target MSM and IDUs. Second, counseling and education
interventions ought to provide a greater focus on HIV-positive
persons. And lastly, more funds should be allocated to those at
high risk rather than the general population. As expected, annual
incidence is highest given no allocation of funds and minimized
under the model’s optimized allocation of the budget.
Relative to no investment of funds, the baseline and optimal
allocation scenarios avert 29,035 and 60,271 HIV infections,
respectively. Given the programmatic annual budget of $327
million, this implies a cost of $56,311 per infection averted for the
baseline as compared to no allocation and $27,128 per infection
averted for the optimal allocation as compared to no allocation.
Therefore, both the current baseline and the optimal allocation of
funds can be considered cost-saving when compared to the HIV
lifetime treatment costs. The baseline and optimal scenarios
allocate the same budget amount so a cost per infection averted
relating both scenarios cannot be inferred. The undiscounted
expenditures total $1.6 billion while the total medical cost of
treating the infections should they not be averted would be $11
billion under the current allocation strategy and $22 billion under
the optimized allocation. In the incremental budget scenario, the
marginal infections averted decreases and the cost per infection
averted increases as the annual budget increases reflecting the
decreased rate at which new infections are averted given
additional funding. At the lowest budget level, funds are spent
on the most cost-effective interventions and target groups, as the
budget increases and the maximum capacity constraints are
reached for those most cost-effective interventions and target
groups, the additional funds are allocated to less cost-effective
targets thereby increasing the cost per infection averted. None-
theless, even at $500 million per year, the lifetime HIV treatment
cost of $367,000 [32] exceeds the estimated cost per infection
averted by $332,000 indicating a cost-saving level of investment.
Given the many inputs and outputs to our model, sensitivity
analysis is not straightforward. Our objective in sensitivity analysis
was to evaluate whether the main model recommendations are
upheld throughout reasonable variations in the input data. Of over
100 sensitivity analysis scenarios conducted, only 9 scenarios
altered the key results presented in Table 2 by more than ten
percentage points. However, those scenarios tended to reinforce
the model’s recommended focus on MSM. The budget constraint
scenario highlights the critical importance of testing, targeting
high-risk groups and diagnosed positives. The classic epidemic
control theory of focusing on high-transmission core groups [33]
endorses our results.
Our model is a simplified representation of the actual allocation
process of DHAP’s HIV prevention resources and thus translating
the model’s output into practice can be difficult. The model
assumed that all members of high-risk population subgroups are
reachable and can be perfectly targeted with interventions. This
simplifying assumption may lead to an overestimation of the
model’s impact because some target population members cannot
be easily reached (and may not even know that they or their
partner are at risk for HIV) and programs for these populations
will have to contact some persons who are not target population
Table 2. Allocated proportion of budget.
Baseline Model
Allocation by intervention
Counseling and education 51% 39%
Testing 49% 61%
Allocation by intervention and risk group
Testing the general population 23% 0%
Testing MSM 6% 36%
Testing IDUs 3% 11%
Testing HRH 16% 14%
Counseling and education for the general population 6% 0%
Counseling and education for MSM 17% 15%
Counseling and education for IDUs 8% 0%
Counseling and education for HRH 20% 24%
Allocation by intervention and race/ethnicity
a
Testing blacks 12% 21%
Testing Hispanics 5% 9%
Testing others 9% 31%
Counseling and education for blacks 20% 15%
Counseling and education for Hispanics 12% 20%
Counseling and education for others 13% 4%
Allocation to counseling and education by serostatus
Counseling and education for diagnosed positives 11% 100%
Counseling and education for susceptibles
b 89% 0%
aMay not total 100%. Includes funds reaching to the 3 risk groups only, not the
general population.
bUndiagnosed positive persons are not distinguishable from susceptible
persons so they are targeted together.
doi:10.1371/journal.pone.0037545.t002
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programmatic efficiency assumed in the model cannot be achieved
in real-world programs. Nonetheless, our model provides insights
on causal relationships and helps us to identify areas where
prevention programs can have the most impact.
Results of the HPTN052 randomized control trial among
serodiscordant couples indicated that antiretroviral therapy
reduces incidence of HIV transmission to the negative partner
by 89% [8]. Our model does not explicitly consider antiretroviral
treatment costs or the variation in HIV transmission rates
associated with viral load suppression and stage of disease.
However, early diagnosis and treatment reduces HIV transmission
so the benefits of HIV diagnoses may be underestimated in this
analysis and an even greater focus on testing than suggested by our
model results may be warranted.
We made linear assumptions on scalability in the intervention
cost and outcome functions of the model; and the shape of such
functions may make a difference in the optimal allocation of funds
[34,35]. Economic evaluations (such as cost-effectiveness analysis)
of HIV prevention programs typically consider one funding level
and their results do not inform on the additional benefit to be
gained (or lost) through increasing or decreasing the investment
[36,37,38]. While our model structure could support more
complex functions, the true shape of such functions is not known
and no reliable data exist to support them.
The per-person intervention costs in our model were largely
derived from microcosting methods where all cost items relating to
an intervention are detailed and cumulated. In contrast with
program budget methods where the overall allocated budget is
simply divided by the number of persons served, microcosting
leads to an underestimate of per-person cost [39]. In actuality,
federally allocated funds are not typically spent completely on the
direct costs of implementing programs; some portion may be spent
on the indirect costs of organizations that implement the
interventions and other entities involved in getting funds to those
organizations. For example, DHAP allocates funds to state health
Figure 2. Model allocation to intervention types by budget amount.
doi:10.1371/journal.pone.0037545.g002
Figure 3. Model allocation to risk groups by budget amount.
doi:10.1371/journal.pone.0037545.g003
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fund community-based organizations to deliver an intervention.
Microcosting does not include the additional funds spent
channeling the resources through these levels to the intended
intervention. Though the method we applied may overestimate
the numbers of persons that can be reached given the overall
budget constraint, the budget constraint scenario presented
mitigates this limitation. If the overage associated with indirect
costs is 60%, then the available budget for program spending
would be about $200 million, and that scenario echoes the main
conclusions of the model.
As with most studies, input data are often being revised and
updated. All data inputs were reviewed internally by a panel of 25
persons within the CDC, data were then validated through an
external peer review process involving by 18 experts. We plan to
publish updates of this analysis, including the effects of newly
implemented programs, including the Expanded HIV Testing
Initiative for populations disproportionately affected by HIV,
primarily African Americans.
Models cannot encompass all the dynamic, complex and often
qualitative realities of HIV resource allocation or be expected to
provide prescriptive results [40]. Resource allocation models for
the control of infectious diseases, such as the one presented here,
are intended to provide guidance on improving the allocation of
funds; they are not designed to provide accurate epidemic
projections. Such models are typically comprised of an optimiza-
tion component that sequentially supplies allocation scenarios to
an epidemic component which projects infections until the optimal
allocation is found. This process can easily reach millions of
iterations and depends on the number of variables and constraints;
therefore, the epidemic component must be kept simple and
efficient. More comprehensive epidemic models that are neither
bound to an optimization engine nor anchored to a time horizon
that reflects a budget cycle can be designed to measure epidemic
growth more precisely over time. Given the aforementioned
considerations, our model results are not intended to make
epidemic projections over time, though their interpretation as a
measure of the difference in impact between scenarios is robust.
Our results have, in part, provided the impetus for other
programs, such as the Expanded HIV Testing Initiative. A recent
analysis of the Initiative suggests that the program achieved a
return of $1.95 for every dollar invested by CDC [41]. Lastly,
according to the National HIV/AIDS Strategy (NHAS), intensi-
fying prevention efforts for MSM, IDUs, black and Hispanic men
and women, and increasing the percentage of people living with
HIV who know their serostatus is required to reduce annual HIV
incidence [42]. The main conclusions of the HIV resource
allocation model serve to substantiate and provide rational
economic evidence for the NHAS goals. Decision makers
responsible for the allocation of DHAP’s programmatic funds
report that the national HIV resource allocation model, along with
program and other data, provides valuable guidance to target
resources and improve the impact of HIV prevention efforts in the
United States.
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